Brought to you by 
Pulmonx raises $32mm through its Series C venture round
05 Mar 2010
Executive Summary
Two years after withdrawing its IPO, Pulmonx (devices to diagnose and treat pulmonary disorders) has raised $32mm through its Series C venture round. New backers HealthCap and Kleiner Perkins Caufield & Byers, which co-led the financing and each contribute a board member, were joined by current shareholders DeNovo Ventures, Latterell Venture Partners, MedVenture Associates, Montreux Equity Partners, and Posco BioVentures and nine undisclosed investors. The company is preparing for the commercial launch of its Chartis pulmonary assessment system and Zephyr endobronchial valve for emphysema.
Deal Industry
- Medical Devices
-
Medical Devices
- Diagnostic Equipment & Supplies
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pulmonx raises $32mm through its Series C venture round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice